一项随机开放标签试验:评估并比较新型液体六价DTwP-Hib/Hep B-IPV(EasySix™)与已上市联合疫苗在健康婴儿中的免疫原性和安全性
该开放标签随机多中心试验将284名6-10周龄健康婴儿按1:1随机分组,接受三剂受试疫苗EasySix™或对照疫苗Pentavac SD®联合Imovax Polio®,间隔4周接种。接种后两组均对全部六种疫苗抗原达到血清保护,血清应答率和抗体几何平均滴度可比,反应原性相似且耐受良好;仅报告1例严重不良事件且完全缓解,判定与疫苗无关。研究显示EasySix™的免疫原性和安全性非劣于已上市疫苗。
要点
- 284名6-10周龄婴儿随机1:1接受三剂EasySix™或Pentavac SD®联合Imovax Polio®,间隔4周。
- 接种后两组均对全部六种疫苗抗原达到血清保护,血清应答率与抗体几何平均滴度可比。
- 两组反应原性相似且耐受良好,仅1例严重不良事件完全缓解且判定与疫苗无关。
核心结论
- EasySix™疫苗的免疫原性和安全性特征非劣于已上市的Pentavac SD®联合Imovax Polio®疫苗。
研究设计与样本
- 开放标签、随机、多中心试验,284名6-10周龄健康婴儿按1:1随机分组,接受三剂受试或对照疫苗,间隔4周接种。
- 免疫原性通过检测基线和接种后抗体应答、比较达到血清保护的受试者比例来判定;安全性通过随访期征集性(局部和全身)及非征集性不良事件发生率评估。
主要发现
- 接种后,两组疫苗均对全部六种疫苗抗原达到血清保护。
- EasySix™组与Pentavac SD®-Imovax Polio®组所有疫苗成分的血清应答率及抗体几何平均滴度可比。
- 两组反应原性特征相似且耐受良好,所有不良事件完全缓解且无后遗症。
- 仅报告1例严重不良事件,完全缓解,判定与所接种疫苗无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Immunogenicity and safety of a newly developed liquid DTwP-Hib/HepB-IPV hexavalent vaccine (EasySix™) was evaluated and compared with administration of commercially licensed Pentavac SD® (DTwP-HepB/Hib) and Imovax Polio® vaccine in an open-label, randomized multi-centric trial. 284 participants, aged 6-10weeks, randomized in a 1:1 allocation, received three doses of test or comparator vaccines, administered 4weeks apart. Immunogenicity of the vaccines was determined by measuring the baseline and post-vaccination antibody responses and comparing the proportions of subjects achieving seroprotection against the vaccine antigens; safety was evaluated in terms of solicited (local and systemic) and unsolicited incidences in the follow up phase. Post-vaccination, seroprotection was achieved against all six vaccine antigens in both vaccine groups. The seroresponse rate as well as geometric mean titers of antibody for all vaccine components were comparable between EasySix™ and Pentavac SD®-Imovax Polio® group. Both vaccines had similar reactogenicity profiles and were well tolerated; all adverse events resolved completely without any sequelae. Only one serious adverse event was reported that completely resolved; it was regarded unconnected to the vaccine administered. This study demonstrated that immunogenicity and safety profiles of EasySix™ vaccine, manufactured by Panacea Biotec Ltd, are non-inferior to the commercially available vaccines. CLINICAL TRIAL REGISTRATION: CTRI/2015/02/005578.
引用
- Mohanty L, Sharma S, Behera B, et al. A randomized, open label trial to evaluate and compare the immunogenicity and safety of a novel liquid hexavalent DTwP-Hib/Hep B-IPV (EasySix™) to licensed combination vaccines in healthy infants. Vaccine. 2018. PMID: 29580640. doi:10.1016/j.vaccine.2017.09.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。